Related Experiment Videos
Prevention of Left Ventricular Remodeling After Myocardial Infarction
Martin St John Sutton1, Victor A. Ferrari
1Division of Cardiovascular Medicine, University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, 9022 East Gates Pavilion, 3400 Spruce Street, Philadelphia, PA 19104, USA. suttonm@mail.med.upenn.edu
Insights
Early restoration of blood flow after myocardial infarction (MI) reduces adverse left ventricular remodeling. Medications like beta-blockers and ACE inhibitors are crucial for managing remodeling and preventing recurrent MI.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Pharmacology
Background:
- Postinfarction left ventricular remodeling is a significant complication following acute myocardial infarction (MI).
- This remodeling process begins early and can persist for months to years, impacting cardiac function.
- Early re-establishment of arterial blood flow is linked to reduced ventricular volumes and less remodeling.
Purpose of the Study:
- To review the therapeutic strategies for managing left ventricular remodeling after acute myocardial infarction.
- To highlight the critical timing of reperfusion therapies and the role of pharmacologic agents.
Main Methods:
- Review of current clinical guidelines and evidence regarding post-MI management.
- Analysis of the efficacy of various pharmacologic agents (antiplatelets, statins, beta-blockers, ACE inhibitors, ARBs, spironolactone) and interventional procedures (PCI, surgery).
Main Results:
- Acute percutaneous coronary intervention (PCI) or thrombolytic therapy is critical for early reperfusion.
- Antiplatelet agents and statins reduce recurrent MI.
- Beta-blockers and ACE inhibitors effectively attenuate remodeling, with combined use showing greater efficacy.
- Angiotensin II receptor blockers are an alternative for ACE inhibitor-intolerant patients.
- Spironolactone offers benefits in reducing fibrosis.
- Surgical revascularization is useful in selected cases.
Conclusions:
- Timely reperfusion is paramount in limiting adverse left ventricular remodeling post-MI.
- Pharmacologic management with agents like beta-blockers, ACE inhibitors, and spironolactone plays a vital role in attenuating remodeling.
- Future therapies may focus on modulating the extracellular matrix to further reduce remodeling.
Abstract:
Postinfarction left ventricular remodeling begins early after acute myocardial infarction and may continue for months to years afterward. Early re-establishment of flow in the occluded artery is associated with smaller left ventricular cavity volumes and reduced remodeling. Acute percutaneous coronary intervention (PCI) or thrombolytic therapy (for patients more than 1 hour away from a catheterization facility) as early as possible after symptoms is critical. Late reperfusion (PCI more than 12 hours after infarction) may prove useful, and this will be determined by the results of ongoing clinical trials. Recurrent MI is reduced by antiplatelet agents (aspirin in most patients) and by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Intravenous nitroglycerin may limit early (initial 24 hours) dilatation following infarction, but long-term use in asymptomatic patients is not efficacious. Beta- adrenergic receptor antagonists and angiotensin-converting enzyme (ACE) inhibitors have independent efficacy in attenuating the early and late phases of remodeling. The combined use of a beta-blocker and an ACE inhibitor has greater efficacy than either agent alone, provided they are tolerated hemodynamically. Although angiotensin II receptor antagonists have similar efficacy to ACE inhibitors and have fewer side effects, the angiotensin II receptor blockers should be reserved for patients intolerant to ACE inhibitors. In patients requiring diuretic therapy, spironolactone is preferred because of its salutary properties regarding extracellular matrix remodeling, specifically in reducing fibrosis. Surgical revascularization with or without associated mitral valve repair is useful in selected patients with severe ischemic mitral regurgitation or hibernating myocardium. New therapies directed at modulating the remodeling process may focus on manipulating the components of the extracellular matrix to reduce the deleterious impact of this process.